OUR TEAM

Our Board of Directors

  • Dr. Martin Riediker

    CHAIRMAN OF THE BOARD

    Martin has extensive experience working with numerous firms in the Biotech, Medtech, and Chemical industries. He served in roles including Global Business Head, CTO, and Chief Innovation Officer in the US and Europe. He is in the Board of multiple start-ups and provides support as Business Angel. Martin is an Alumnus of ETH Zürich, Princeton University , and Harvard University.

  • Giovanna Libralon

    BOARD MEMBER

    Giovanna received her Bachelor’s degree in Pharmaceutical Chemistry and Technology. She brings 20 years of pharmaceutical experience in development and manufacturing of active pharmaceutical ingredients, covering different roles in R&D, Operations, and commercial functions for both Pharmaceutical and CDMO industries.

  • David Brown

    BOARD MEMBER

    David Brown has a technology and startup background. He has been a very active angel investor for 15 years across a range of deep-tech areas encompassing software, sensors, robotics, nano- and med-tech. He is an experienced startup Board Director, a member of Innosuisse's innovation council and the chair of the Bridge Proof of Concept (a SNSF/Innosuisse joint initiative which is the first funding for many Swiss university spinouts). He has been an early believer in INOFEA, investing from 2014.

  • Dr. Anne Timm

    BOARD MEMBER

    Anne has a PhD in cell biology and graduated at the Technical University of Darmstadt. During her time in the Chemical Industry, she was involved in a couple of biotechnical projects before she moved in various sales and business development roles and leading business lines and sales organizations.

Our Team

Team
Dr. Anne Timm, CEO
Dr. Anne Timm, CEO

Anne worked for more than 30 years in the chemical industry holding various positions like Business Line Head (P&L), Global Key Account Manager and Head of Sales for various markets like pharma, medical devices, consumer care and crop protection. Anne started in 2018 as CBO at INOFEA and moved into the role as CEO in March 2019.

Prof. Dr. Patrick Shahgaldian, CSO
Prof. Dr. Patrick Shahgaldian, CSO

Patrick is Professor at the University of Applied Sciences (FHNW) near Basel, where he leads the Molecular Nanotechnology research group. He is the main inventor of the enzzen®- technology platform and co-founder of INOFEA. Patrick is the author of more than 90 peer-reviewed publications and of a dozen of patents. He is not on INOFEA’s payroll but supports INOFEA with his scientific experience

Dr. Rita Correro, CTO
Dr. Rita Correro, CTO

Rita started at INOFEA in 2017, first as Head of R&D and she is now responsible as CTO for R&D, Production and QA and as Group Leader for biocatalysis in small molecule API manufacturing. She developed INOFEA’s technology at FHNW as postdoc and graduated with a PhD in Biology focusing on Biochemistry at ETH Zurich.

Dr. Agnese Pisano, R&D Group Leader IVT
Dr. Agnese Pisano, R&D Group Leader IVT

Agnese earned her Bachelor of Science in Biological Sciences and her Master of Science in Molecular and Industrial Biotechnologies from the University of Naples "Federico II". She completed an internship at the Centre for Protein Engineering of the University of Liège, where she studied protein-RNA interactions. Agnese then earned her PhD in RNA Biology from the University of Zurich. She has joined INOFEA as R&D Group Leader for mRNA IVT (In Vitro Transcription). Agnese is an expert in RNA processing enzymes and is passionate about the field of IVT. Her expertise significantly contributes to the company's strategic focus on Biologics. Agnese has developed valuable leadership skills, making her a strong asset in driving INOFEA's ambitious goals.

Dr. Aaron Debon, R&D Group Leader Enzymatic Bioconjugation
Dr. Aaron Debon, R&D Group Leader Enzymatic Bioconjugation

Aaron completed his master’s degree in interdisciplinary sciences, followed by a PhD thesis on protein engineering at ETH Zürich. During his tenure at Novartis as a postdoc, he focused on enzymatic peptide modification and bioconjugation. At INOFEA, he contributes his expertise as an R&D group leader in bioconjugation to further advance INOFEA‘s vision of enzymatically produced bioconjugates.

Dr. Marie Ruch, Scientist
Dr. Marie Ruch, Scientist

Marie earned a master’s degree in molecular and supramolecular chemistry from the University of Strasbourg along with an engineering degree from the ECPM (European School of Chemistry, Polymers and Materials Science). She worked as a research associate at NovAlix before starting her PhD at the University of Strasbourg. During her PhD, she focused on the development of red/NIR emitting dyes and their bioconjugation to nanobodies. During her postdoc at ICMUB (Institute of Molecular Chemistry from the University of Burgundy), she was responsible for R&D bioconjugation studies for industrial partners. At INOFEA, she contributes to enzymatic bioconjugation and biocatalysis.

Dr. Tina Uroda, Scientist
Dr. Tina Uroda, Scientist

Tina earned a master’s degree in Biotechnology and Pharmaceutical R&D from the University of Rijeka, followed by a PhD in Biochemistry and Molecular Biology from Université Grenoble Alpes, working at the prestigious European Molecular Biology Laboratory (EMBL). During her PhD, she investigated the correlation between RNA structure and function. During her postdoc as a Marie Curie Postdoctoral Fellow, she explored RNA function in humans by applying CRISPR technology. Tina joined INOFEA as Scientist for Enzymatic RNA In Vitro Transcription (IVT) and Downstream Purification, bringing her expertise in RNA biology to apply INOFEA’s technology to sustainable mRNA manufacturing.